Objectives
The Nurse Learning Module will provide an overview of some of the common treatments for lymphoma/CLL. We will describe how the landscape is evolving with the introduction of new therapies over recent years.
The module will also explore the nursing implications of how new therapies for lymphoma & CLL have changed patient care.
At the completion of module four participants will have an in-depth knowledge of some of the new therapies available for lymphoma/CLL patients.
- The nurse will develop an understanding of how and why treatment decisions are made for lymphoma/CLL patients
- Have an understanding about the different treatments available for lymphoma/CLL patients
- Why are lymphoma/CLL patients treated with different types of therapies
- Treatment management of aggressive vs indolent lymphoma
- How do these therapies work?
- Common side effects of newer therapies
- Nursing implications of treating patients with new therapies other than chemotherapy
Module four presentations
Part 1: The evolving treatment landscape for lymphoma/CLL
Dr Katharine Lewis, Lymphoma Clinical/Research Fellow, Sir Charles Gairdner Hospital, Perth
Katharine is a Haematology Clinical/Research Fellow from the UK, who is working at Sir Charles Gairdner Hospital and Linear from August 2018. She graduated from the University of Nottingham in the UK in 2007 and has since completed most of her post graduate training in Nottingham, which is a large, tertiary referral centre for both malignant and non-malignant haematology, including stem cell transplantation.
Her particular field of interest is lymphoma, and she is working as a Lymphoma Clinical/Research Fellow at Sir Charles Gairdner Hospital.
Part 2: Patient care in the era of new therapies for lymphoma/CLL
Helena Furdas, Lymphoma Clinical Nurse Consultant, Sir Charles Gairdner Hospital, Perth.
Helena graduated from nursing at Curtin University in 2009 and shortly thereafter began her haematology experience in 2010 whilst working at Royal Perth Hospital on the Bone Marrow Transplant Unit. Since then she has continued to work in haematology and in 2015 transitioned with the State Centre for Allogeneic stem cell transplant to Fiona Stanley Hospital. Here she enjoyed working in the Cancer Centre providing care for patients to keep them well, happy and out of hospital.
As a new member of the Sir Charles Gairdner Hospital team Helena is excited to be the Lymphoma CNC and looks forward to helping patients navigate their journey through lymphoma.
Post assessment
To be eligible for a certificate of attendance, you need to complete a short assessment. The certificate will be emailed to you shortly after you have submitted the assessment.
Evaluation Survey
Please complete our short evaluation survey (if you haven’t done so already) to let us know if we met your expectations and ensure we meet your future learning needs.
Further reading and resources
New developments in immunotherapy for lymphoma
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121050/
Rituximab
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma
https://www.nejm.org/doi/full/10.1056/nejmoa011795
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomised study of the German low-grade Lymphoma Study Group
https://ashpublications.org/blood/article/106/12/3725/109746/Frontline-therapy-with-rituximab-added-to-the
Obinutuzumab
Immunochemotherapy with Obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety
Brentuximab
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
https://ashpublications.org/blood/article/132/25/2639/39577/Five-year-PFS-from-the-AETHERA-trial-of
Pembrolizumab
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classical Hodgkin lymphoma
Ibrutinib
Targeting BTK with ibrutinib in relapsed or refractory mantle cell lymphoma
https://www.nejm.org/doi/full/10.1056/nejmoa1306220
How I treat patients with ibrutinib?
https://ashpublications.org/blood/article/131/4/379/38474/How-I-treat-CLL-patients-with-ibrutinib
Venetoclax
Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukaemia
https://www.nejm.org/doi/10.1056/NEJMoa1713976
